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http:WHAT THIS PAPER ADDS
This study is the ﬁrst study showing feasibility, safety and efﬁcaciousness of mechanochemical endovenous
ablation (MOCA) of small saphenous vein (SSV) insufﬁciency.Objective: This study evaluated the feasibility, safety and 1-year results of mechanochemical endovenous
ablation (MOCA) of small saphenous vein (SSV) insufﬁciency.
Design: Prospective cohort study.
Materials and methods: Fifty consecutive patients were treated for primary SSV insufﬁciency with MOCA using
the ClariVein device and polidocanol. Initial technical success, complications, patient satisfaction and visual
analogue scale (VAS) pain score were assessed. Anatomic and clinical success was assessed at 6 weeks and at 1
year.
Results: Initial technical success of MOCA was 100%. At the 6-week assessment, all treated veins were
occluded. The 1-year follow-up duplex showed anatomic success in 94% (95% conﬁdence interval, 0.87e1).
Venous clinical severity score (VCSS) decreased signiﬁcantly from 3.0 (interquartile range (IQR) 2e5) before
treatment to 1.0 (IQR 1e3, P < 0.001) at 6 weeks and to 1.0 (IQR 1e2, P < 0.001) at 1 year. Median procedural
VAS score for pain was 2 (IQR 2e4). No major complications were observed, especially no nerve injury.
Conclusions: MOCA is a safe, feasible and efﬁcacious technique for treatment of SSV insufﬁciency. One-year
follow-up shows a 94% anatomic success rate and no major complications.
 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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overall prevalence between 20% and 60%.1 The effect of
venous insufﬁciency on health-related quality of life is
substantial and comparable with other chronic diseases
such as arthritis, diabetes and cardiovascular disease.2
These problems are mostly associated with insufﬁciency of
great saphenous veins (GSVs); however, insufﬁciency of the
small saphenous vein (SSV) is responsible in 15% of patients
with varicose veins.3
Until the 1990s, high ligation, with or without surgical
stripping, was the preferred option for venous insufﬁciency,
although there was no standard in surgical treatment of SSV
insufﬁciency. The introduction of minimally invasive endo-
thermal catheter modalities, including endovenous laser
ablation (EVLA) and radiofrequency ablation (RFA), hasrresponding author. Tel.: þ31 30 6093376; fax: þ31 30 6036578.
il address: doekeboersma@gmail.com (D. Boersma).
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//dx.doi.org/10.1016/j.ejvs.2012.12.004revolutionised the treatment of varicose veins. These have
become the preferred techniques, with high success
rates.4,5
Most endovenous ablation techniques are based on
heating of the vein wall and, therefore, require the instil-
lation of tumescent anaesthesia. Despite tumescent,
thermal-associated complications, such as prolonged pain
and skin burn, have been described. The risk of sural nerve
injury is a major concern in surgical stripping and endove-
nous thermal ablation of the SSV.6e8 The main focus of
improving therapy is currently aimed at reducing pain
during and after treatment, as well as reducing heat-related
trauma.
The recently introduced mechanochemical endovenous
ablation (MOCA) technique using the ClariVein catheter
(Vascular Insights, Madison, CT, USA) is unique: mechanical
injury to the venous endothelium is combined with simul-
taneous catheter-guided infusion of a liquid sclerosant. No
heat is generated and, therefore, tumescent is not required.
Recent studies have proven that MOCA is a feasible and
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evaluate the initial results and the 1-year follow-up of
MOCA using the ClariVein catheter in combination with
polidocanol in SSV insufﬁciency.
MATERIALS AND METHODS
This study included all patients with symptomatic, primary
SSV insufﬁciency treated in the St. Antonius Hospital,
Nieuwegein, and the Rijnstate Hospital, Arnhem, The
Netherlands, from June 2010 to April 2011. Physical
examination was performed by a vascular surgeon or
a vascular physician assistant before treatment, and the
CEAP classiﬁcation and venous clinical severity score (VCSS)
were assessed. All patients underwent duplex ultrasonog-
raphy (DUS) of the deep and superﬁcial veins of the
affected leg. SSV insufﬁciency was deﬁned as a retrograde
ﬂow >0.5 s after calf compression while standing.
Inclusion criteria were age >18 years, duplex-conﬁrmed
SSV incompetence at sapheno-popliteal junction, long-
segment SSV insufﬁciency (>10 cm), SSV diameter between
2.5 and 11 mm, C2e6 EP AS4 PR and written informed
consent. Exclusion criteria were previous surgical treatment
of the SSV, history of ipsilateral deep vein thrombosis (DVT),
ipsilateral GSV or deep venous insufﬁciency, peripheral
arterial occlusive disease or use of anticoagulants. Patients
with allergy, pregnancy or lactation or other contraindica-
tions for the use of polidocanol were excluded.
Ethical approval for research was granted.Intervention:
All interventions were performed with the ClariVein
device, combined with polidocanol (Aethoxysklerol,
KreusslerPharma, Wiesbaden, Germany), by a vascular
surgeon or a physician assistant on an outpatient basis. All
physicians had previously performed >10 MOCA proce-
dures using the ClariVein in the GSV. No analgesia or
antibiotics were administered before treatment.
The MOCA technique has been previously described.9
Brieﬂy, the ClariVein device is a disposable 2.6F single-
lumen catheter for infusing liquid sclerosant. A metal wire,
ﬁtted distally with a small ball, runs through the catheter
(Fig. 1). It is hypothesised that rotation of the wireFigure 1. a: ClariVein device consists of motor handle unit (H) and infu
from catheter (CL). Acknowledgement: Figure A is reproduced wit perm
International Society of Endovascular Specialists.(3000 rpm) induces intimal injury and disperses the liquid
sclerosant.
The entire length of the ﬁrst 15 SSVs was treated
with 1.5% polidocanol. In the later 35 cases, the proximal SSV
(10e15 cm) was treated with 2 ml polidocanol (2%) and the
remainder with polidocanol (1.5%). The protocol was altered
because preliminary results in GSVs showed improved
occlusion rates with the latter regimen. The total amount of
used liquid sclerosant is noted in Table 1. In none of the
patients the allowed daily dose of 2 mg kg1 day1 is
exceeded. No concomitant phlebectomies were performed.
DUS was performed to conﬁrm occlusion of treated vein.
Patients wore compression stockings (30e40 mm Hg) contin-
uously for the ﬁrst 24 h and during the daytime for the next 2
weeks. Patients were allowed to perform their daily activities
immediately. No standard analgesics were prescribed.
Outcomes and follow-up protocol
The primary outcome measures were (1) technical success,
deﬁned as the ability to perform procedure as planned and
achieve immediate occlusion after the procedure, and (2)
anatomic success, deﬁned as occlusion of treated vein. A re-
canalised SSV or treatment failure was deﬁned as an open
segment of >10 cm.11
Secondary outcomes included complications, treatment
time, patient satisfaction and procedural pain.
The treatment time (from start of procedure to applying
compression stocking) and length of the treated vein were
noted. Patients were asked to record the level of pain during
treatment on a visual analogue scale (VAS) from0 cm (no pain)
to 10 cm (worst imaginable pain). All patients were scheduled
for a follow-up assessment at 6 weeks and 1 year by a vascular
surgeon, including physical examination, determination of
VCSS and DUS. After 6 weeks, patients were asked to quantify
their satisfaction of the treatment in a 10-point score. In the
case of residual varicosities, sclerotherapy was offered. Any
postprocedural complications were noted. All data were
gathered prospectively and stored in computerised database.
Statistical analysis
Variables are presented as mean with standard deviation
(SD) or range for parametric continuous outcomes, assion catheter (C). b: Dispersion tip (T) protrudes with angulated tip
ission from the Journal of Endovascular Therapy.14 Copyright 2011.
Table 1. Patient demographics and treatment characteristics.
Number of patientsa 50 (100%)
Bilateral SSV insufﬁciency None
Ageb (years) 53 (25e84)
Malea 18 (36%)
Femalea 32 (64%)
Weightb (kg) 76 (48e135)
Dosage of polidocanol 1.5%a 15 (30%)
Dosage of polidocanol 2.0 mL 2%/1.5%a 35 (70%)
C2 Varicose veins
a 26 (52%)
C3 Oedema
a 14 (28%)
C4 Skin changes
a 8 (16%)
C5 Healed ulcer
a 1 (2%)
C6 Active ulcer
a 1 (2%)
SSV diameterc (mm) 4.8 (3.5e7)
Length of treated SSVc (cm) 22 (18e35)
Total volume of polidocanold (mL) 4.4 (1.1)
Total dosage of polidocanold (mg) 72 (19)
Duration of treatment (min)c 20 (15e24)
a Number (percentage of total).
b Mean value (range).
c Median value (interquartile range).
d Mean value (SD). SSV, small saphenous vein.
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and as frequencies and percentages for categoric variables.
KaplaneMeier survival analysis was used to assess
anatomic success rate. The log-rank test was used to
compare anatomic success between the initial protocol
using 1.5% polidocanol and the latter protocol using the
higher dosage. Change in VCSS was analysed with the
Wilcoxon signed rank test. Statistical analyses were per-
formed using Statistical Package for the Social Sciences
(SPSS) 19.0 software (SPSS Inc, Chicago, IL, USA). A value of
P < 0.05 was considered signiﬁcant.
RESULTS
The study included 50 consecutive patients who met the
eligibility criteria. Patient characteristics are described in
Table 1. At 1 year, three patients (6%) were lost to follow-
up: one was free of complaints and refused follow-up, and
the other two did not respond to repeated invitations for
the follow-up assessment.
Occlusion rates
The technical success rate was 100%: all treated SSVs were
occluded on DUS directly after MOCA. At 6 weeks, all
treated veins (50 of 50) remained occluded. In 9 patients
(18%) residual varicosities were treated by sclerotherapy to
optimise cosmetic outcome.
At 1 year, 44 of 47 SSVs were occluded, for an anatomic
success of 94% (95% conﬁdence interval (CI), 0.87e1).
Patients who were lost to follow-up were censored at 6
weeks after treatment. At the 1-year follow-up, re-canal-
isation occurred in 2 of the 15 patients treated with low-
dose polidocanol (anatomic success, 87%; 95%CI, 0.71e1)and in 1 of 32 patients who received the elevated dose of
polidocanol (anatomic success, 97%; 95%CI, 0.91e1). The
difference between these subgroups was not signiﬁcant
(P ¼ 0.187).Pain, patient satisfaction and duration of treatment
The median VAS pain score during treatment was 2 cm (IQR
2e4 cm). The median duration of treatment was 20 min
(IQR 15e24 min). After 6 weeks, median patient satisfac-
tion of the treatment was 8 (IQR 8e9).Venous clinical severity score
At the 6-week follow-up, median VCSS had decreased
signiﬁcantly from 3 (IQR 2e5) pre-MOCA to 1 (IQR 1e3;
P < 0.001). At 1 year after treatment, VCSS remained
signiﬁcantly decreased compared with preprocedural scores
(1 (IQR 1e2), P < 0.001).Complications
No major complications were observed. Importantly, there
were no signs of any nerve injury, and no DVT, skin necrosis,
infection or hyperpigmentation was recorded. Minor
complications included localised ecchymosis (12%), indura-
tion around the access site (12%) and transient superﬁcial
thrombophlebitis of the treated vein (14%). Pain lasted
longer than 1 week in 5 patients (10%), all caused by
superﬁcial thrombophlebitis. After 6 weeks and 1 year, no
additional complications were seen.
DISCUSSION
This study is the ﬁrst describing results of MOCA in
treating SSV insufﬁciency. Technical success was 100%, and
after 6 weeks of follow-up, no re-canalisation was noticed.
At the 1-year follow-up, anatomic success persisted in 44
of 47 patients (94%). An important observation was the
difference in anatomic success between the initial group
treated with 1.5% polidocanol and the later group treated
with 2% polidocanol in the proximal section. Although this
difference is not signiﬁcant, probably because of the small
number of patients, an elevated dosage of liquid scle-
rosant may be a key in optimising occlusion rates in
MOCA.
The treatment of superﬁcial venous insufﬁciency has
changed dramatically in the last decade. Ligation, with or
without surgical stripping, of insufﬁcient saphenous veins
has mostly been replaced by thermal endovenous catheter
therapies, due to their superior efﬁcacy and less invasive
character.12 Results of EVLA for SSV insufﬁciency have
repeatedly been described, with short-term occlusion rates
ranging from 91% to 100%.6,7,13,14 RFA in treatment of
varicosity of the SSV has only been described in a small
series, but shows excellent results.15
Ultrasound-guided foam sclerotherapy (UGFS) is another
widely used minimally invasive technique to ablate varicose
veins. Success rates of UGFS in SSV are 82% after a mean
follow-up of 11 months. Although liquid sclerotherapy is
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be used to treat insufﬁciency of saphenous veins, due to
inferior occlusion rates of 17%e60% at 1 year.4,11,16,17
Two studies describing the safety and the initial results of
MOCA were recently published. Elias et al. showed an
occlusion rate in GSV of 96.7% after MOCA using sodium
tetradecyl sulphate (Sotradecol, AngioDynamics, Queens-
bury, NY, USA) after average follow-up of 260 days. MOCA
combining ClariVein with polidocanol showed occlusion in
97% of treated GSV at 6 weeks after treatment, and partial
re-canalisation was described in 10%. No major complica-
tions occurred, and minor complains were acceptable in
amount and severity.9,10
All modalities in the treatment of varicose veins have
speciﬁc complications. Ecchymosis and postprocedural pain
seem inherent to heat-based therapies. In GSV, MOCA is
associated with signiﬁcantly less postoperative pain
compared with RFA.18 More importantly, in SSV treatment,
the anatomic proximity of the sural nerve poses an addi-
tional risk. In published data, transient sural nerve injury
caused by ELVA varies between 1.3% and 11%.6,11,14,19 In
redo SSV surgery, the incidence of numbness 1 year after
treatment is as high as 28%.20 In general, major complica-
tions, such as skin burns, DVT and pulmonary embolism
after EVLA, seldom occur (<1%). Transient thrombophlebitis
occurred in 14% of patients, comparable with foam scle-
rotherapy and RFA.11 MOCA of the SSV has been proven
to be safe: no major complications, including no sural nerve
injuries, occurred. MOCA eliminates the need for
tumescent anaesthesia, which can be desirable, because it
is time-consuming and requires multiple injections.
Clinical results after endovenous ablation, in general, are
excellent. In our study group, a signiﬁcant decrease in VCSS
wasmeasured at 6weeks and at 1 year of follow-up compared
with preprocedural scores. Patient satisfaction was high.
One of the limitations of this study is that the maximum
diameter of treated SSVs was 11 mm. The technical and
clinical success of MOCA in larger-diameter varicose veins
is still unknown. Pain scores during MOCA were very low.
Postprocedural pain scores were not measured. Further
controlled studies are required to compare pain with other
techniques in SSV ablation. Patients on oral anticoagulants
were excluded; thus, we cannot provide data on the effect
of anticoagulant therapy on MOCA. In contrast to endo-
thermal therapy, anticoagulants might inﬂuence clot
formation and lead to increased re-canalisation.CONCLUSION
MOCA using the ClariVein device and polidocanol
appears to be a safe, feasible and efﬁcacious technique in
the treatment of SSV insufﬁciency. Early and 1-year follow-
up results are promising, with a 94% occlusion rate, no
major complications and low pain scores.
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